Logotipo del repositorio
Logotipo del repositorio
 

COVID-19: Unveiling the Neuropsychiatric Maze -- From Acute to Long-Term Manifestations

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorAriza Ezpinoza, Daniela Del Carmen
dc.contributor.authorCastellar Visbal, Lily
dc.contributor.authorMarquina Stagg, Maria Angelica
dc.contributor.authorRivera-Porras, Diego
dc.contributor.authorGalban, Nestor
dc.contributor.authorSanteliz , Raquel
dc.contributor.authorGutiérrez-Rey, Melissa
dc.contributor.authorParra, Heliana
dc.contributor.authorVargas-Manotas, José
dc.contributor.authorTorres, Wheeler
dc.contributor.authorQuintana Espinosa, Laura Lucia
dc.contributor.authorManzano, Alexander
dc.contributor.authorCudris-Torres, Lorena
dc.contributor.authorBermudez, Valmore
dc.date.accessioned2025-02-05T17:02:25Z
dc.date.available2025-02-05T17:02:25Z
dc.date.issued2024
dc.description.abstractThe SARS-CoV-2 virus has spread rapidly despite implementing strategies to reduce its transmission. The disease caused by this virus has been associated with a diverse range of symptoms, including common neurological manifestations such as dysgeusia, anosmia, and myalgias. Additionally, numerous cases of severe neurological complications associated with this disease have been reported, including encephalitis, stroke, seizures, and Guillain–Barré syndrome, among others. Given the high prevalence of neurological manifestations in this disease, the objective of this review is to analyze the mechanisms by which this virus can affect the nervous system, from its direct invasion to aberrant activation of the immune system and other mechanisms involved in the symptoms, including neuropsychiatric manifestations, to gain a better understanding of the disease and thus facilitate the search for effective therapeutic strategies.eng
dc.format.mimetypepdf
dc.identifier.citationAriza, D.; Castellar-Visbal, L.; Marquina, M.; Rivera-Porras, D.; Galbán, N.; Santeliz, R.; Gutiérrez-Rey, M.; Parra, H.; Vargas-Manotas, J.; Torres, W.; et al. COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations. Biomedicines 2024, 12, 1147. https:// doi.org/10.3390/biomedicines12061147eng
dc.identifier.doihttps://doi.org/10.3390/biomedicines12061147
dc.identifier.issn22279059
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16218
dc.language.isoeng
dc.publisherMDPIspa
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.subject.keywordsSARS-CoV-2eng
dc.subject.keywordsCOVID-19eng
dc.subject.keywordsNeuroinflammationeng
dc.subject.keywordsEncephalitiseng
dc.subject.keywordsStrokeeng
dc.subject.keywordsGuillain–Barré Syndromeeng
dc.titleCOVID-19: Unveiling the Neuropsychiatric Maze -- From Acute to Long-Term Manifestationseng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científicospa
dcterms.referencesWorld Health Organization. COVID-19 Deaths|WHO COVID-19; World Health Organization: Geneva, Switzerland, 2024.spa
dcterms.referencesPerumal, R.; Shunmugam, L.; Naidoo, K.; Karim, S.S.A.; Wilkins, D.; Brechot, G.-D.A.C.; Parthasarathy, S.; Vahlne, A.; Nikolich, J.Ž. Long COVID: A review and proposed visualization of the complexity of long COVID. Front. Immunol. 2023, 14, 1117464.spa
dcterms.referencesDavis, H.E.; McCorkell, L.; Vogel, J.M.; Topol, E.J. Long COVID: Major findings, mechanisms and recommendations. Nature reviews. Microbiology 2023, 21, 133–146.spa
dcterms.referencesAl-Husinat, L.; Nusir, M.; Al-Gharaibeh, H.; Alomari, A.A.; Smadi, M.M.; Battaglini, D.; Pelosi, P. Post-COVID-19 syndrome symptoms after mild and moderate SARS-CoV-2 infection. Front. Med. 2022, 9, 1017257.spa
dcterms.referencesCastanares-Zapatero, D.; Chalon, P.; Kohn, L.; Dauvrin, M.; Detollenaere, J.; de Noordhout, C.M.; Jong, C.P.-D.; Cleemput, I.; Van den Heede, K. Pathophysiology and mechanism of long COVID: A comprehensive review. Ann. Med. 2022, 54, 1473–1487.spa
dcterms.referencesRodriguez-Morales, A.J.; Lopez-Echeverri, M.C.; Perez-Raga, M.F.; Quintero-Romero, V.; Valencia-Gallego, V.; Galindo-Herrera, N.; López-Alzate, S.; Sánchez-Vinasco, J.D.; Gutiérrez-Vargas, J.J.; Mayta-Tristan, P.; et al. The global challenges of the long COVID-19 in adults and children. Travel. Med. Infect. Dis. 2023, 54, 102606.spa
dcterms.referencesGorbalenya, A.E.; Baker, S.C.; Baric, R.S.; de Groot, R.J.; Drosten, C.; Gulyaeva, A.A.; Ziebuh, J. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020, 5, 536–544.spa
dcterms.referencesKim, J.M.; Chung, Y.S.; Jo, H.J.; Lee, N.J.; Kim, M.S.; Woo, S.H.; Park, S.; Kim, J.W.; Kim, H.M.; Han, M.G. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong Public Health Res. Perspect. 2020, 11, 3–7.spa
dcterms.referencesZou, X.; Chen, K.; Zou, J.; Han, P.; Hao, J.; Han, Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020, 14, 185–192.spa
dcterms.referencesHamming, I.; Timens, W.; Bulthuis, M.L.C.; Lely, A.T.; Navis, G.V.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004, 203, 631–637.spa
dcterms.referencesHelms, J.; Tacquard, C.; Severac, F.; Leonard-Lorant, I.; Ohana, M.; Delabranche, X.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Gandet, F.F.; et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020, 46, 1089–1098.spa
dcterms.referencesKim, I.C.; Kim, J.Y.; Kim, H.A.; Han, S. COVID-19-related myocarditis in a 21-year-old female patient. Eur. Heart J. 2020, 41, 1859.spa
dcterms.referencesWei, X.S.; Wang, X.; Niu, Y.R.; Ye, L.L.; Peng, W.B.; Wang, Z.H.; Yang, W.B.; Yang, B.H.; Zhang, J.C.; Ma, W.L.; et al. Diarrhea Is Associated With Prolonged Symptoms and Viral Carriage in Corona Virus Disease 2019. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2020, 18, 1753–1759.spa
dcterms.referencesRossi, G.M.; Delsante, M.; Pilato, F.P.; Gnetti, L.; Gabrielli, L.; Rossini, G.; Re, M.C.; Cenacchi, G.; Affanni, P.; Colucci, M.E.; et al. Kidney Biopsy Findings in a Critically Ill COVID-19 Patient with Dialysis-Dependent Acute Kidney Injury: A Case against "SARS-CoV-2 Nephropathy. Kidney Int. Rep. 2020, 5, 1100–1105.spa
dcterms.referencesWang, Y.; Liu, S.; Liu, H.; Li, W.; Lin, F.; Jiang, L.; Li, X.; Xu, P.; Zhang, L.; Zhao, L.; et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J. Hepatol. 2020, 74, 807–816.spa
dcterms.referencesRong-Hui, D.; Li-Rong, L.; Cheng-Qing, Y.; Wen, W.; Tan-Ze, C.; Ming, L.; Guang-Yun, G.; Juan, D.; Chun-Lan, Z.; Qi, Z.; et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: A prospective cohort study. Eur. Respir. J. 2020, 55, 2000524.spa
dcterms.referencesPetrilli, C.M.; Jones, S.A.; Yang, J.; Rajagopalan, H.; O’Donnell, L.; Chernyak, Y.; Horwitz, L.I. Factors associated with hospitalization and critical illness among 4103 patients with COVID-19 disease in New York City. MedRxiv 2020.spa
dcterms.referencesHuang, C.; Wang, Y.; Li, X.; Zhao, R.L.J.; Hu, Y.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506.spa
dcterms.referencesSpinato, G.; Fabbris, C.; Polesel, J.; Cazzador, D.; Borsetto, D.; Hopkins, C.; Boscolo-Rizzo, P. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA Neurol. 2020, 323, 2089–2090.spa
dcterms.referencesLechien, R.; Chiesa-Estomba, C.M.; De Siati, D.R.; Horoi, M.; Le Bon, S.D.; Rodriguez, A.; Dequanter, D.; Blecic, S.; El Afia, F.; Distinguin, L.; et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. Eur. Arch. Oto-Rhino-Laryngol. 2020, 277, 2251–2261.spa
dcterms.referencesBerger, J.R. COVID-19 and the nervous system. J. Neurovirol. 2020, 26, 143–148.spa
dcterms.referencesMao, L.; Jin, H.; Wang, M.; Hu, Y.; Chen, S.; He, Q.; Hu, B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77, 683–690.spa
dcterms.referencesHaroun, M.W.; Dieiev, V.; Kang, J.; Barbi, M.; Nia, S.F.M.; Gabr, M.; Eman, G.; Kajita, G.; Swedish, K. Rhabdomyolysis in COVID-19 Patients: A Retrospective Observational Study. Cureus 2021, 13, e12552.spa
dcterms.referencesVaratharaj, A.; Thomas, N.; Ellul, M.A.; Davies, N.W.S.; Pollak, T.A.; Tenorio, E.L.; Easton, S.M.A.; Breen, G.; Zandi, M.; Coles, J.P.; et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet Psychiatry 2020, 7, 875–882.spa
dcterms.referencesAhmed, J.O.; Ahmad, S.A.; Hassan, M.N.; Kakamad, F.H.; Salih, R.Q.; Abdulla, B.A.; Salih, A.M. Post COVID-19 neurological complications; a meta-analysis. Ann. Med. Surg. 2022, 76, 103440.spa
dcterms.referencesWang, F.; Kream, R.M.; Stefano, G.B. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2020, 26, e928996.spa
dcterms.referencesMullaguri, N.; Sivakumar, S.; Battineni, A.; Anand, S.; Vanderwerf, J. COVID-19 Related Acute Hemorrhagic Necrotizing Encephalitis: A Report of Two Cases and Literature Review. Cureus 2021, 13, e14236.spa
dcterms.referencesOrozco-Hernández, J.P.; Marin-Medina, D.S.; Sánchez-Duque, J.A. Neurological manifestations of SARS-CoV-2 infection. Semergen 2020, 46 (Suppl. S1), 106–108.spa
dcterms.referencesReichard, R.R.; Kashani, K.B.; Boire, N.A.; Constantopoulos, E.; Guo, Y.; Lucchinetti, C.F. Neuropathology of COVID-19: A spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020, 140, 1–6.spa
dcterms.referencesJaunmuktane, Z.; Mahadeva, U.; Green, A.; Sekhawat, V.; Barrett, N.A.; Childs, L.; Shankar-Hari, M.; Thom, M.; Jäger, H.R.; Brandner, S. Microvascular injury and hypoxic damage: Emerging neuropathological signatures in COVID-19. Acta Neuropathol. 2020, 140, 397–400.spa
dcterms.referencesvon Weyhern, C.H.; Kaufmann, I.; Neff, F.; Kremer, M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet 2020, 395, e109.spa
dcterms.referencesCoolen, T.; Lolli, V.; Sadeghi, N.; Rovai, A.; Trotta, N.; Taccone, F.S.; Creteur, J.; Henrard, S.; Goffard, J.C.; Dewitte, O.; et al. Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology 2020, 95, e2016–e2027.spa
dcterms.referencesKanberg, N.; Ashton, N.J.; Andersson, L.M.; Yilmaz, A.; Lindh, M.; Nilsson, S.; Price, R.W.; Blennow, K.; Zetterberg, H.; Gisslén, M. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 2020, 95, e1754–e1759.spa
dcterms.referencesAhmed, M.U.; Hanif, M.; Ali, M.J.; Haider, M.A.; Kherani, D.; Memon, G.M.; Sattar, A. Neurological manifestations of COVID-19 (SARS-CoV-2): A review. Front. Neurol. 2020, 11, 518.spa
dcterms.referencesDesforges, M.; Le Coupanec, A.; Dubeau, P.; Bourgouin, A.; Lajoie, L.; Dubé, M.; Talbot, P.J. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses 2019, 12, 14.spa
dcterms.referencesYeh, E.A.; Collins, A.; Cohen, M.E.; Duffner, P.K.; Faden, H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics 2004, 113, e73–e76.spa
dcterms.referencesDubé, M.; Le Coupanec, A.; Wong, A.H.M.; Rini, J.M.; Desforges, M.; Talbot, P.J. Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43. J. Virol. 2018, 92, e00404-18.spa
dcterms.referencesChan, J.F.; Chan, K.H.; Choi, G.K.; To, K.K.; Tse, H.; Cai, J.P.; Yeung, M.L.; Cheng, V.C.; Chen, H.; Che, X.Y.; et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: Implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 2013, 207, 1743–1752.spa
dcterms.referencesPamies, D.; Barreras, P.; Block, K.; Makri, G.; Kumar, A.; Wiersma, D.; Smirnova, L.; Zang, C.; Bressler, J.; Christian, K.M.; et al. A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity. ALTEX 2017, 34, 362–376.spa
dcterms.referencesBullen, C.K.; Hogberg, H.T.; Bahadirli-Talbott, A.; Bishai, W.R.; Hartung, T.; Keuthan, C.; Looney, M.M.; Pekosz, A.; Romero, J.C.; Sillé, F.C.M.; et al. Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2. ALTEX 2020, 37, 665–671.spa
dcterms.referencesMesci, P.; de Souza, J.S.; Martin-Sancho, L.; Macia, A.; Saleh, A.; Yin, X.; Snethlage, C.; Adams, J.W.; Avansini, S.H.; Herai, R.H.; et al. SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir. PLoS Biol. 2022, 20, e3001845.spa
dcterms.referencesHou, Y.; Li, C.; Yoon, C.; Leung, O.W.; You, S.; Cui, X.; Chan, J.F.; Pei, D.; Cheung, H.H.; Chu, H. Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids. Signal Transduct. Target. Ther. 2022, 7, 381.spa
dcterms.referencesPuelles, V.G.; Lütgehetmann, M.; Lindenmeyer, M.T.; Sperhake, J.P.; Wong, M.N.; Allweiss, L.; Chilla, S.; Heinemann, A.; Wanner, N.; Liu, S.; et al. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 2020, 383, 590–592.spa
dcterms.referencesMoriguchi, T.; Harii, N.; Goto, J.; Harada, D.; Sugawara, H.; Takamino, J.; Ueno, M.; Sakata, H.; Kondo, K.; Myose, N.; et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2020, 94, 55–58.spa
dcterms.referencesQi, J.; Zhou, Y.; Hua, J.; Zhang, L.; Bian, J.; Liu, B.; Zhao, Z.; Jin, S. The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection. Int. J. Environ. Res. Public Health 2021, 18, 284.spa
dcterms.referencesHoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280.e8.spa
dcterms.referencesAntinone, S.E.; Smith, G.A. Retrograde axon transport of herpes simplex virus and pseudorabies virus: A live-cell comparative analysis. J. Virol. 2010, 84, 1504–1512.spa
dcterms.referencesMacGibeny, M.A.; Koyuncu, O.O.; Wirblich, C.; Schnell, M.J.; Enquist, L.W. Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. PLoS Pathog. 2018, 14, e1007188.spa
dcterms.referencesvan Riel, D.; Verdijk, R.; Kuiken, T. The olfactory nerve: A shortcut for influenza and other viral diseases into the central nervous system. J. Pathol. 2015, 235, 277–287.spa
dcterms.referencesPoliti, L.S.; Salsano, E.; Grimaldi, M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. JAMA Neurol. 2020, 77, 1028–1029.spa
dcterms.referencesMeinhardt, J.; Radke, J.; Dittmayer, C.; Franz, J.; Thomas, C.; Mothes, R.; Laue, M.; Schneider, J.; Brünink, S.; Greuel, S.; et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021, 24, 168–175.spa
dcterms.referencesBrann, D.H.; Tsukahara, T.; Weinreb, C.; Lipovsek, M.; Van den Berge, K.; Gong, B.; Chance, R.; Macaulay, I.C.; Chou, H.J.; Fletcher, R.B.; et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 2020, 6, eabc5801.spa
dcterms.referencesNampoothiri, S.; Sauve, F.; Ternier, G.; Fernandois, D.; Coelho, C.; Imbernon, M.; Prevot, V. The hypothalamus as a hub for putative SARS-CoV-2 brain infection. BioRxiv 2020.spa
dcterms.referencesProust, A.; Queval, C.J.; Harvey, R.; Adams, L.; Bennett, M.; Wilkinson, R.J. Differential effects of SARS-CoV-2 variants on central nervous system cells and blood-brain barrier functions. J. Neuroinflamm. 2023, 20, 184.spa
dcterms.referencesMilanetti, E.; Miotto, M.; Di Rienzo, L.; Nagaraj, M.; Monti, M.; Golbek, T.W.; Gosti, G.; Roeters, S.J.; Weidner, T.; Otzen, D.E.; et al. In-Silico Evidence for a Two Receptor Based Strategy of SARS-CoV-2. Front. Mol. Biosci. 2021, 8, 690655.spa
dcterms.referencesSigrist, C.J.; Bridge, A.; Le Mercier, P. A potential role for integrins in host cell entry by SARS-CoV-2. Antivir. Res. 2020, 177, 104759.spa
dcterms.referencesVerma, S.; Lo, Y.; Chapagain, M.; Lum, S.; Kumar, M.; Gurjav, U.; Luo, H.; Nakatsuka, A.; Nerurkar, V.R. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier. Virology 2009, 385, 425–433.spa
dcterms.referencesTabor-Godwin, J.M.; Ruller, C.M.; Bagalso, N.; An, N.; Pagarigan, R.R.; Harkins, S.; Gilbert, P.E.; Kiosses, W.B.; Gude, N.A.; Cornell, C.T.; et al. A novel population of myeloid cells responding to coxsackievirus infection assists in the dissemination of virus within the neonatal CNS. J. Neurosci. Off. J. Soc. Neurosci. 2010, 30, 8676–8691.spa
dcterms.referencesPaniz-Mondolfi, A.; Bryce, C.; Grimes, Z.; Gordon, R.E.; Reidy, J.; Lednicky, J.; Sordillo, E.M.; Fowkes, M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J. Med. Virol. 2020, 92, 699–702.spa
dcterms.referencesBonetto, V.; Pasetto, L.; Lisi, I.; Carbonara, M.; Zangari, R.; Ferrari, E.; Punzi, V.; Luotti, S.; Bottino, N.; Biagianti, B.; et al. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front. Immunol. 2022, 13, 1070379.spa
dcterms.referencesPatil, S.; Patil, S.; Gondhali, G.; Toshniwal, S. Immune Dysregulation during and after COVID-19: “Tomorrow Never Dies” Situation. J. Transl. Crit. Care Med. 1793, 5, e00024.spa
dcterms.referencesWright, H.; Alex, P.; Nguyen, T.; Bader, T.; Gurakar, A.; Sebastian, A.; Gonzales, L.; Wallis, G.; Naylor, M.; Dozmorov, I.; et al. Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. Dig. Dis. Sci. 2005, 50, 1793–1803. [spa
dcterms.referencesRuan, O.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46, 846–848.spa
dcterms.referencesZhao, N.; Di, B.; Xu, L.L.; NLRP, T. COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021, 61, 2–15.spa
dcterms.referencesSankowski, R.; Mader, S.; Valdés-Ferrer, S.I. Systemic inflammation and the brain: Novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front. Cell. Neurosci. 2015, 9, 28.spa
dcterms.referencesDalakas, C.M. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol. Neuroimmunol. Neuroinflamm. 2020, 7, e781.spa
dcterms.referencesDalakas, C.M. Pathogenesis of immune-mediated neuropathies. Biochim. Biophys. Acta 2015, 185, 658–666.spa
dcterms.referencesBurr, T.; Barton, C.; Doll, E.; Lakhotia, A.; Sweeney, M. N-Methyl-d-Aspartate Receptor Encephalitis Associated with COVID-19 Infection in a Toddler. Pediatr. Neurol. 2021, 114, 75–76.spa
dcterms.referencesDurovic, E.; Bien, C.; Bien, C.G.; Isenmann, S. MOG antibody-associated encephalitis secondary to COVID-19: Case report. BMC Neurol. 2021, 21, 414.spa
dcterms.referencesYiannopoulou, K.; Vakrakou, A.G.; Anastasiou, A.; Sourdi, N.G.A.; Tzartos, J.S.; Kilidireas, C.; Dimitrakopoulos, A. Cerebrospinal Fluid Anti-Neuronal Autoantibodies in COVID-19-Associated Limbic Encephalitis with Acute Cerebellar Ataxia and Myoclonus Syndrome: Case Report and Literature Review. Diagnostics 2023, 13, 2055.spa
dcterms.referencesFlannery, P.; Yang, I.; Keyvani, M.; Sakoulas, G. Acute Psychosis Due to Anti-N-Methyl D-Aspartate Receptor Encephalitis Following COVID-19 Vaccination: A Case Report. Front. Neurol. 2021, 12, 764197.spa
dcterms.referencesAbdelhady, M.; Husain, M.A.; Hawas, Y.; Elazb, M.A.; Mansour, L.S.; Mohamed, M.; Abdelwahab, M.M.; Aljabali, A.; Negida, A. Encephalitis following COVID-19 Vaccination: A Systematic Review. Vaccines 2023, 11, 576.spa
dcterms.referencesda Costa, M.D.; Rato, M.L.; Cruz, D.; Valadas, A.; Antunes, A.P.; Albuquerque, L. Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection. J. Neuroimmunol. 2021, 361, 577739.spa
dcterms.referencesStoian, A.; Stoian, M.; Bajko, Z.; Maier, S.; Andone, S.; Cioflinc, R.A.; Motataianu, A.; Barcutean, L.; Balasa, R. Autoimmune Encephalitis in COVID-19 Infection: Our Experience and Systematic Review of the Literature. Biomedicines 2022, 10, 774.spa
dcterms.referencesLeng, A.; Shah, M.; Ahmad, S.A.; Premraj, L.W.K.; Bassi, G.L.; Pardo, C.A.; Choi, A.; Cho, S.M. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells 2023, 12, 816.spa
dcterms.referencesRoche, J.A.; Roche, R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2020, 34, 7265–7269.spa
dcterms.referencesMcCarthy, C.G.; Wilczynski, S.; Wenceslau, C.F.; Webb, R.C. A new storm on the horizon in COVID-19: Bradykinin-induced vascular complications. Vasc. Pharmacol. 2021, 137, 106826.spa
dcterms.referencesSidarta-Oliveira, D.; Jara, C.P.; Ferruzzi, A.J.; Skaf, M.S.; Velander, W.H.; Araujo, E.P.; Velloso, L.A. SARS-CoV-2 receptor is co-expressed with elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cell. Sci. Rep. 2020, 10, 19522.spa
dcterms.referencesTabassum, A.; Iqbal, M.S.; Sultan, S.; Alhuthali, R.A.; Alshubaili, D.I.; Sayyam, R.S.; Abyad, L.M.; Qasem, A.H.; Arbaeen, A.F. Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19. Mediat. Inflamm. 2022, 2022, 7423537.spa
dcterms.referencesTong, J.Y.; Wong, A.; Zhu, D.; Fastenberg, J.H.; Tham, T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol. Head. Neck Surg. Off. J. Am. Acad. Otolaryngol. Head Neck Surg. 2020, 163, 3–11.spa
dcterms.referencesHelms, J.; Kremer, S.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Kummerlen, C.; Collange, O.; Boulay, C.; Fafi-Kremer, S.; Ohana, M.; et al. Neurologic Features in Severe SARS-CoV-2 Infection. N. Engl. J. Med. 2020, 382, 2268–2270.spa
dcterms.referencesYang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020, 8, 475–481.spa
dcterms.referencesPilotto, A.; Odolini, S.; Masciocchi, S.; Comelli, A.; Volonghi, I.; Gazzina, S.; Nocivelli, S.; Pezzini, A.; Focà, E.; Caruso, A.; et al. Steroid-Responsive Encephalitis in Coronavirus Disease 2019. Ann. Neurol. 2020, 88, 423–427.spa
dcterms.referencesBeyrouti, R.; Adams, M.E.; Benjamin, L.; Cohen, H.; Farmer, S.F.; Goh, Y.Y.; Humphries, F.; Jäger, H.R.; Losseff, N.A.; Perry, R.J.; et al. Characteristics of ischaemic stroke associated with COVID-19. J. Neurol. Neurosurg. Psychiatry 2020, 91, 889–891.spa
dcterms.referencesKarimi, N.; Razavi, A.S.; Rouhani, N. Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report. Iran. Red. Crescent Med. J. 2020, 22, e102828.spa
dcterms.referencesCaamaño, D.S.J.; Beato, R.A. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2020, 77, 230–232.spa
dcterms.referencesArabi, Y.M.; Harthi, A.; Hussein, J.; Bouchama, A.; Johani, S.; Hajeer, A.H.; Saeed, B.T.; Wahbi, A.; Saedy, A.; AlDabbagh, T.; et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 2015, 43, 495–501.spa
dcterms.referencesLi, Y.; Li, H.; Fan, R.; Wen, B.; Zhang, J.; Cao, X.; Wang, C.; Song, Z.; Li, S.; Li, X.; et al. Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children. Intervirology 2016, 59, 163–169.spa
dcterms.referencesSiow, I.; Lee, K.S.; Zhang, J.J.Y.; Saffari, S.E.; Ng, A. Encephalitis as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes, and predictors. Eur. J. Neurol. 2021, 28, 3491–3502.spa
dcterms.referencesZhang, P.P.; He, Z.C.; Yao, X.H.; Tang, R.; Ma, J.; Luo, T.; Zhu, C.; Li, T.R.; Liu, X.; Zhang, D.; et al. COVID-19-associated monocytic encephalitis (CAME): Histological and proteomic evidence from autopsy. Signal Transduct. Target. Ther. 2023, 8, 24.spa
dcterms.referencesAllahyari, F.; Molaee, H.; Nejad, J.H. COVID-19 vaccines and neurological complications: A systematic review. Zeitschrift fur Naturforschung. J. Biosci. 2022, 78, 1–8.spa
dcterms.referencesZhou, L.; Zhang, M.; Wang, J.; Gao, J. Sars-Cov-2: Underestimated damage to nervous system. Travel Med. Infect. Dis. 2020, 36, 101642.spa
dcterms.referencesBernard-Valnet, R.; Pizzarotti, B.; Anichini, A.; Demars, Y.; Russo, E.; Schmidhauser, M.; Cerutti-Sola, J.; Rossetti, A.O.; Pasquier, R.D. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. Eur. J. Neurol. 2020, 27, e43–e44.spa
dcterms.referencesPoyiadji, N.; Shahin, G.; Noujaim, D.; Stone, M.; Patel, S.; Griffith, B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology 2020, 296, E119–E120.spa
dcterms.referencesJomaa, N.; El Halabi, T.; Melhem, J.; Dib, G.; Ghosn, Y.; Hourani, M.; Nasreddine, W.; Beydoun, A. COVID-19-Associated Acute Asymmetric Hemorrhagic Necrotizing Encephalopathy: A Case Report. Neurohospitalist 2022, 12, 371–376.spa
dcterms.referencesNandan, R.; Sharma, G.; Nandolia, K.; Saxena, S.; Verma, P.K. Acute Hemorrhagic Necrotizing Encephalopathy in Patients with COVID-19. Ann. Indian Acad. Neurol. 2022, 25, 511–513.spa
dcterms.referencesDixon, L.; Varley, J.; Gontsarova, A.; Mallon, D.; Tona, F.; Muir, D.; Luqmani, A.; Jenkins, I.H.; Nicholas, R.; Jones, B.; et al. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol. Neuroimmunol. Neuroinflamm. 2020, 7, e789.spa
dcterms.referencesLazarte-Rantes, C.; Guevara-Castañón, J.; Romero, L.; Guillén-Pinto, D. Acute Necrotizing Encephalopathy Associated with SARS-CoV-2 Exposure in a Pediatric Patient. Cureus 2021, 13, e15018.spa
dcterms.referencesCiolac, D.; Crivorucica, I.; Zota, E.; Gorincioi, N.; Efremova, D.; Manea, D.; Crivorucica, V.; Ciocanu, M.; Groppa, S.A. Extensive cerebellar involvement and cognitive impairment in COVID-19-associated acute necrotizing encephalopathy. Ther. Adv. Neurol. Disord. 2021, 14, 1756286420985175.spa
dcterms.referencesDelamarre, L.; Gollion, C.; Grouteau, G.; Rousset, D.; Jimena, G.; Roustan, J.; Gaussiat, F.; Aldigé, E.; Gaffard, C.; Duplantier, J.; et al. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J. Neurol. Neurosurg. Psychiatry 2020, 91, 1004–1006.spa
dcterms.referencesPongpitakmetha, T.; Hemachudha, P.; Rattanawong, W.; Thanapornsangsuth, P.; Viswanathan, A.; Hemachudha, T. COVID-19 related acute necrotizing encephalopathy with extremely high interleukin-6 and RANBP2 mutation in a patient with recently immunized inactivated virus vaccine and no pulmonary involvement. BMC Infect. Dis. 2022, 22, 640.spa
dcterms.referencesYu, H.H.; Qin, C.; Chen, M.; Wang, W.; Tian, D.S. D-dimer level is associated with the severity of COVID-19. Thromb. Res. 2020, 195, 219–225.spa
dcterms.referencesLuo, W.; Liu, X.; Bao, K.; Huang, C. Ischemic stroke associated with COVID-19: A systematic review and meta-analysis. J. Neurol. 2022, 269, 1731–1740.spa
dcterms.referencesTroccoli, H.D.M. Tratamiento trombolítico del ictus isquémico agudo. Gac. Méd. Caracas 2020, 121, 183–198.spa
dcterms.referencesTay, M.Z.; Poh, C.M.; Rénia, L.; MacAry, P.A.; Ng, L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020, 20, 363–374.spa
dcterms.referencesLi, Y.; Li, M.; Wang, M.; Zhou, Y.; Chang, J.; Xian, Y.; Wang, D.; Mao, L.; Jin, H.; Hu, B. Acute cerebrovascular disease following COVID-19: A single center, retrospective, observational study. Stroke Vasc. Neurol. 2020, 5, 279–284.spa
dcterms.referencesMedetalibeyoglu, A.; Kaytaz, M.; Senkal, N.; Genc, S.; Aktar, I.; Omer, B.; Oncul, O.; Tukek, T. Would Tracking Coagulation Together with Inflamation Markers be a Prospect for COVID-19 Disease Prognosis? Clin. Lab. 2022, 68.spa
dcterms.referencesElkind, M. Why now? Moving from stroke risk factors to stroke triggers. Curr. Opin. Neurol. 2007, 20, 51–57.spa
dcterms.referencesGiannis, D.; Ziogas, I.A.; Gianni, P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2020, 127, 104362.spa
dcterms.referencesPanigada, M.; Bottino, N.; Tagliabue, P.; Grasselli, G.; Novembrino, C.; Chantarangkul, V.; Pesenti, A.; Peyvandi, F.; Tripodi, A. ypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. JTH 2020, 18, 1738–1742.spa
dcterms.referencesAsakura, H.; Ogawa, H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int. J. Hematol. 2021, 113, 45–57.spa
dcterms.referencesBoss, G.R.; Seegmiller, J.E. Age-related physiological changes and their clinical significance. West. J. Med. 1981, 135, 434–440.spa
dcterms.referencesTrejo-Gabriel-Galán, J.M. Stroke as a complication and prognostic factor of COVID-19. Ictus como complicación y como factor pronóstico de COVID-19. Neurologia 2020, 35, 318–322.spa
dcterms.referencesStafstrom, C.E.; Carmant, L. Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb. Perspect. Med. 2015, 5, a022426.spa
dcterms.referencesHussaini, H.; Rogers, S.; Kataria, S.; Uddin, K.; Mohamed, K.H.; Mohamed, A.S.; Tariq, F.; Ahmad, S.; Awais, A.; Ahmed, Z.; et al. COVID-19-Induced Seizures: A Meta-Analysis of Case Series and Retrospective Cohorts. Cureus 2022, 14, e28633.spa
dcterms.referencesDiaz, C.E.; Bueno, A.C.; Zeas, M.V.; Klinger, L.G.; Núñez, A.H.T.; García Alvarado, L.; Dalgo Pozo, A. Estatus epiléptico en niños: Aspectos generales diagnósticos y terapéuticos. Arch. Venez. Farmacol. Ter. 2019, 38, 377–381.spa
dcterms.referencesYavarpour-Bali, H.; Ghasemi-Kasman, M. Update on neurological manifestations of COVID-19. Life Sci. 2020, 257, 118063.spa
dcterms.referencesYe, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 2020, 80, 607–613.spa
dcterms.referencesSinghi, P. Infectious causes of seizures and epilepsy in the developing world. Dev. Med. Child Neurol. 2011, 53, 600–609.spa
dcterms.referencesAydin, S.; Özdemir, C.; Gündüz, A.; Kiziltan, M.E. Seizures in patients with respiratory disease—A retrospective single center study. Arq. Neuro-Psiquiatr. 2020, 78, 247–254.spa
dcterms.referencesNiazkar, H.R.; Zibaee, B.; Nasimi, A.; Bahri, N. The neurological manifestations of COVID-19: A review article. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2020, 41, 1667–1671.spa
dcterms.referencesYing, W.; Qian, Y.; Kun, Z. Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic. Res. Soc. Adm. Pharm. RSAP 2021, 17, 1978–1983.spa
dcterms.referencesRogers, J.P.; Chesney, E.; Oliver, D.; Pollak, T.A.; McGuire, P.; Fusar-Poli, P.; Zandi, M.S.; Lewis, G.; David, A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020, 7, 611–627.spa
dcterms.referencesFerrando, S.J.; Klepacz, L.; Lynch, S.; Tavakkoli, M.; Dornbush, R.; Baharani, R.; Smolin, Y.; Bartell, A. COVID-19 Psychosis: A Potential New Neuropsychiatric Condition Triggered by Novel Coronavirus Infection and the Inflammatory Response? Psychosomatics 2020, 61, 551–555.spa
dcterms.referencesTroyer, E.A.; Kohn, J.N.; Hong, S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 2020, 87, 34–39.spa
dcterms.referencesOtani, K.; Fukushima, H.; Matsuishi, K. COVID-19 delirium and encephalopathy: Pathophysiology assumed in the first 3 years of the ongoing pandemic. Brain Disord. 2023, 10, 100074.spa
dcterms.referencesUygun, Ö.; Ertaş, M.; Ekizoğlu, E.; Bolay, H.; Özge, A.; Orhan, E.K.; Çağatay, A.A.; Baykan, B. Headache characteristics in COVID-19 pandemic-a survey study. J. Headache Pain 2020, 21, 121.spa
dcterms.referencesRodrigues, A.N.; Dias, A.R.N.; Paranhos, A.C.M.; Silva, C.C.; Bastos, T.D.R.; de Brito, B.B.; da Silva, N.M.; de Sousa, E.J.S.; Quaresma, J.A.S.; Falcão, L.F.M. Headache in long COVID as disabling condition: A clinical approach. Front. Neurol. 2023, 14, 1149294.spa
dcterms.referencesChhabra, N.; Grill, M.F.; Singh, R.B.H. Post-COVID Headache: A Literature Review. Curr. Pain Headache Rep. 2022, 26, 835–842.spa
dcterms.referencesPanariello, F.; Cellini, L.; Speciani, M.; De Ronchi, D.; Atti, A.R. How Does SARS-CoV-2 Affect the Central Nervous System? A Working Hypothesis. Front. Psychiatry 2020, 11, 582345.spa
dcterms.referencesIsmail, I.I.; Salama, S. Association of CNS demyelination and COVID-19 infection: An updated systematic review. J. Neurol. 2022, 269, 541–576.spa
dcterms.referencesLotan, I.; Nishiyama, S.; Manzano, G.S.; Lydston, M.; Levy, M. COVID-19 and the risk of CNS demyelinating diseases: A systematic review. Front. Neurol. 2022, 13, 970383.spa
dcterms.referencesGombolay, G.; Hallman-Cooper, J. COVID-19 and the Pandemic-Related Aspects in Pediatric Demyelinating Disorders. Semin. Pediatr. Neurol. 2023, 46, 101055.spa
dcterms.referencesKhair, A.M.; Nikam, R.; Husain, S.; Ortiz, M.; Kaur, G. Para and Post-COVID-19 CNS Acute Demyelinating Disorders in Children: A Case Series on Expanding the Spectrum of Clinical and Radiological Characteristics. Cureus 2022, 14, e23405.spa
dcterms.referencesGarg, R.K.; Paliwal, V.K.; Gupta, A. Spinal cord involvement in COVID-19: A review. J. Spinal Cord Med. 2023, 46, 390–404.spa
dcterms.referencesSchulte, E.C.; Hauer, L.; Kunz, A.B.; Sellner, J. Systematic review of cases of acute myelitis in individuals with COVID-19. Eur. J. Neurol. 2021, 28, 3230–3244.spa
dcterms.referencesAlKetbi, R.; AlNuaimi, D.; AlMulla, M.; AlTalai, N.; Samir, M.; Kumar, N.; AlBastaki, U. Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings. Radiol. Case Rep. 2020, 15, 1591–1595.spa
dcterms.referencesMunz, M.; Wessendorf, S.; Koretsis, G.; Tewald, F.; Baegi, R.; Krämer, S.; Geissler, M.; Reinhard, M. Acute transverse myelitis after COVID-19 pneumonia. J. Neurol. 2020, 267, 2196–2197.spa
dcterms.referencesLee, Y.; Min, P.; Lee, S.; Kim, S.W. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. J. Korean Med. Sci. 2020, 35, e174.spa
dcterms.referencesVaira, L.A.; Deiana, G.; Fois, A.G.; Pirina, P.; Madeddu, G.; De Vito, A.; Babudieri, S.; Petrocelli, M.; Serra, A.; Bussu, F.; et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. Head Neck 2020, 42, 1252–1258.spa
dcterms.referencesMao, L.W.M.; Chen, S.; He, Q.; Chang, J.; Hong, C.; Hu, B. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. MedRxiv 2020.spa
dcterms.referencesVaira, L.A.; Salzano, G.; Fois, A.G.; Piombino, P.; De Riu, G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int. Forum Allergy Rhinol. 2020, 10, 1103–1104.spa
dcterms.referencesTsai, L.K.; Hsieh, S.T.; Chang, Y.C. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol. Taiwanica 2005, 14, 113–119.spa
dcterms.referencesNetland, J.; Meyerholz, D.K.; Moore, S.; Cassell, M.; Perlman, S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008, 82, 7264–7275.spa
dcterms.referencesXu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020, 12, 8.spa
dcterms.referencesTsuruoka, S.; Wakaumi, M.; Ioka, T.; Yamamoto, H.; Ando, H.; Sugimoto, K.; Fujimura, A. Angiotensin II receptor blocker-induces blunted taste sensitivity: Comparison of candesartan and valsartan. Br. J. Clin. Pharmacol. 2005, 60, 204–207spa
dcterms.referencesDietsch, A.M.; Solomon, N.P.; Steele, C.M.; Pelletier, C.A. The effect of barium on perceptions of taste intensity and palatability. Dysphagia 2014, 29, 96–108.spa
dcterms.referencesNguyen, T.P.; Taylor, R.S. Guillain-Barre Syndrome. I; StatPearls Publishing: St. Petersburg, FL, USA, 2023.spa
dcterms.referencesScheidl, E.; Canseco, D.D.; Hadji-Naumov, A.; Bereznai, B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. J. Peripher. Nerv. Syst. JPNS 2020, 25, 204–207.spa
dcterms.referencesMarenco, A.; Lozada, J.M. Unusual Clinical Presentation of Guillain Barre Syndrome: A Case Report; Ciencia e Innovación en Salud: Barranquilla, Colombia, 2018.spa
dcterms.referencesZhao, H.; Shen, D.; Zhou, H.; Liu, J.; Chen, S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol. 2020, 19, 383–384.spa
dcterms.referencesFarzi, M.A.; Ayromlou, H.; Jahanbakhsh, N.; Bavil, P.H.; Janzadeh, A.; Shayan, F.K. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. J. Neuroimmunol. 2020, 346, 577294.spa
dcterms.referencesToscano, G.; Palmerini, F.; Ravaglia, S.; Ruiz, L.; Invernizzi, P.; Cuzzoni, M.G.; Franciotta, D.; Baldanti, F.; Daturi, R.; Postorino, P.; et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N. Engl. J. Med. 2020, 382, 2574–2576.spa
dcterms.referencesChan, J.L.; Ebadi, H.; Sarna, J.R. Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection. Can. J. Neurol. Sci. J. Can. Sci. Neurol. 2020, 47, 852–854.spa
dcterms.referencesArnaud, S.; Budowski, C.; Tin, S.N.W.; Degos, B. Post SARS-CoV-2 Guillain-Barré syndrome. Clin. Neurophysiol. 2020, 131, 1652–1654.spa
dcterms.referencesSedaghat, Z.; Karimi, N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2020, 76, 233–235.spa
dcterms.referencesGutiérrez-Ortiz, C.; Méndez-Guerrero, A.; Rodrigo-Rey, S.; Pedro-Murillo, E.S.; Bermejo-Guerrero, L.; Gordo-Mañas, R.; de Aragón-Gómez, F.; Benito-León, J. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020, 95, e601–e605.spa
dcterms.referencesUmapathi, T. Does COVID-19 cause axonal GBS? J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2020, 78, 448.spa
dcterms.referencesVirani, A.R.E.; Hanson, T.; Haag, A.; Elrufay, R.; Cheema, T.; Bhanot, N. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases 2020, 20, e00771.spa
dcterms.referencesOttaviani, D.; Boso, F.; Tranquillini, E.; Gapeni, I.; Pedrotti, G.; Cozzio, S.; Guarrera, G.M.; Giometto, B. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): A case report from an Italian COVID-hospital. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2020, 41, 1351–1354.spa
dcterms.referencesEl Otmani, H.; El Moutawakil, B.; Rafai, M.A.; El Benna, N.; El Kettani, C.; Soussi, M.; El Mdaghri, N.; Barrou, H.; Afif, H. Covid-19 and Guillain-Barré syndrome: More than a coincidence! Rev. Neurol. 2020, 176, 518–519.spa
dcterms.referencesAlberti, P.; Beretta, S.; Piatti, M.; Karantzoulis, A.; Piatti, M.L.; Santoro, P.; Viganò, M.; Giovannelli, G.; Pirro, F.; Montisano, D.A.; et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol. Neuroimmunol. Neuroinflamm. 2020, 7, e741spa
dcterms.referencesOrganización Mundial de la Salud. Salud Mental y COVID-19: Datos Iniciales Sobre las Repercusiones de la Pandemia; Organización Mundial de la Salud: Geneva, Switzerland, 2022.spa
dcterms.referencesNicolini, H. Depression and anxiety during COVID-19 pandemic. Cir. Cir. 2020, 88, 542–547.spa
dcterms.referencesBraga, J.; Lepra, M.; Kish, S.J.; Rusjan, P.M.; Nasser, Z.; Verhoeff, N.; Vasdev, N.; Bagby, M.; Boileau, I.; Husain, M.I.; et al. Neuroinflammation After COVID-19 with Persistent Depressive and Cognitive Symptoms. JAMA Psychiatry 2023, 80, 787–795.spa
dcterms.referencesSadock, B.; Sadock, V.; Ruiz, P. Kaplan y Sadock. Manual de Psiquiatría Clínica; Lippincott Williams & Wilkins (LWW): Philadelphia, PA, USA, 2018.spa
dcterms.referencesGonzález-González, C. Actualidades en la fisiopatología del trastorno por estrés postraumático (TEPT). Salud Jalisco 2018, 1, 128–134.spa
dcterms.referencesOrganización Panamericana de la Salud, La Pandemia por COVID-19 Provoca un Aumento del 25% en la Prevalencia de la Ansiedad y la Depresión en todo el Mundo. 6 Marzo 2022. Available online: https://www.paho.org/es/noticias/2-3-2022-pandemia-por-covid-19-provoca-aumento-25-prevalencia-ansiedad-depresion-todo (accessed on 15 March 2024).spa
dcterms.referencesGonzález-González, C.; Arvilla-Arce, H.E. Alteraciones neuropsiquiátricas de la enfermedad por COVID-19. Salud Jalisco 2021, 8, 59–64.spa
dcterms.referencesAmerican Psychiatric Association [APA]. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; Arlington: Westport, CT, USA, 2013.spa
dcterms.referencesMcWhirter, L.; Smyth, H.; Hoeritzauer, I.; Couturier, A.; Stone, J.; Carson, A.J. What is brain fog? J. Neurol. Neurosurg. Psychiatry 2023, 94, 321–325.spa
dcterms.referencesAl-Aly, Z.; Rosen, C.J. Long Covid and Impaired Cognition—More Evidence and More Work to Do. N. Engl. J. Med. 2024, 390, 858–860.spa
dcterms.referencesHampshire, A.; Azor, A.; Atchison, C.; Trender, W.; Hellyer, P.J.; Giunchiglia, V.; Husain, M.; Cooke, G.S.; Cooper, E.; Lound, A.; et al. Cognition and Memory after Covid-19 in a Large Community Sample. N. Engl. J. Med. 2024, 390, 806–818.spa
dcterms.referencesHugon, J. Long-COVID: Cognitive deficits (brain fog) and brain lesions in non-hospitalized patients. Presse Medicale 2022, 51, 104090.spa
dcterms.referencesTavassoly, O.; Safavi, F.; Tavassoly, I. Seeding Brain Protein Aggregation by SARS-CoV-2 as a Possible Long-Term Complication of COVID-19 Infection. ACS Chem. Neurosci. 2020, 11, 3704–3706.spa
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
2.68 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca